Applied Clinical Trials-04-01-2021

FDA Reviews Gains, Risks of Accelerated Approval Process

March 25, 2021

View from Washington



FDA is reviewing the record of its accelerated approval program following recent withdrawals of certain key indications for several leading cancer therapies, based on the failure of post-approval studies to document extended benefits of treatment.